Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

Inclusion Criteria: * Females, 18-49 years of age with HPV16 infection and cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1) * HPV16 infection has been confirmed at least twice by a validated HPV test separated by at least 3 months * Satisfactory colposcopy * No clinically significant out of range haematological, renal or hepatic laboratory tests * Normal screening ECG or screening ECG with no clinically significant findings, as judged by the investigator * Negative serum pregnancy test at screening * Agree to use a reliable form of contraception during the whole study period. * Provides written informed consent Exclusion Criteria: * Any vaccination within 6 weeks of day 0 * Active significant viral infections including influenza, CMV, and EBV within 30 days of receiving study treatment * Co-infection with hepatitis B, hepatitis C, or HIV or having other immune deficient states * Current Bacterial Vaginosis (BV) infection * Current high-grade cervical intraepithelial neoplasia (CIN2/3) * Prior history of or current malignancy, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), atypical glandular cells (AGC), adenocarcinoma in situ (AIS) or any suspicion of either micro-invasive or invasive disease * Pregnancy, breastfeeding * Influenza-li…